Periodic acid-Schiff and alcian blue immunohistochemistry to detect mucin in mucinous breast carcinoma

  • Primariadewi Rustamadji Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
  • Jason Wibowo Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
  • Belinda Murtani Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia https://orcid.org/0000-0002-9467-1467
  • Christy Magdalena Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia https://orcid.org/0000-0002-3739-0263
DOI: https://doi.org/10.13181/mji.oa.192768
Keywords: alcian blue, mucin, mucinous carcinoma, periodic acid-Schiff reaction
Abstract viewed: 1326 times
PDF downloaded: 821 times
HTML downloaded: 773 times
EPUB downloaded: 295 times

Abstract

BACKGROUND Detection of mucins has been shown to correlate with several clinicopathological characteristics in patients. Currently, periodic acid-Schiff (PAS) and alcian blue staining methods are the histochemistry staining techniques that are frequently used to detect mucin. This study was aimed to evaluate PAS and alcian blue staining in differentiating mucin characteristics between invasive carcinoma of no special type (ICNST) with mucinous degeneration and mucinous carcinoma.

METHODS This cross-sectional study of 33 cases included biopsies of mucinous breast carcinoma and ICNST with mucin degeneration that were histologically verified using hematoxylin and eosin (H&E) staining. The PAS and alcian blue staining were conducted in the Laboratory of Histochemistry, Department of Anatomical Pathology, Cipto Mangunkusumo Hospital. Data were recorded using SPSS software, version 21 (IBM Corp, USA).

RESULTS There were 17 cases of ICNST with mucinous degeneration and 16 cases of mucinous carcinoma with age varied from 27 to 75 years. PAS had sensitivity of 87.5% and specificity of 41.2%. Alcian blue had sensitivity of 43.8% and specificity of 82.4%.

CONCLUSIONS PAS staining method is better than the alcian blue staining method in distinguishing between ICNST with mucinous degeneration and mucinous carcinoma. In the limited setting laboratory, PAS staining alone can be considered to detect mucin.

Downloads

Download data is not yet available.

References

  1. Global Cancer Observatory. Population fact sheets: Indonesia [Internet]. Lyon: International Agency for Research on Cancer; 2018 [cited 2019 Nov 17]. Available from: http://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf.

  2. Schnitt SJ, Collins LC. Biopsy interpretation of the breast. Philadelphia: Lippincot Williams & Wilkins; 2013.

  3. Kumar V, Abbas AK, Fausto N, Aster JC. Robbins and Cotran pathologic basis of disease. Philadelphia: Saunders Elsevier; 2010.

  4. Mukhopadhyay P, Chakraborty S, Ponnusamy MP, Lakshmanan I, Jain M, Batra SK. Mucin in the pathogenesis of breast cancer: implication in diagnosis, prognosis and therapy. Biochim Biophys Acta. 2011;1815(2):224-40. https://doi.org/10.1016/j.bbcan.2011.01.001

  5. Myers R. Special stain techniques for the evaluation of mucins [Internet]. Illinois: Leica Biosystems; 2009 [cited 2013 Dec 19]. Available from: http://www.leicabiosystems.com/pathologyleaders/special-stain-techniques-for-the-evaluation-of-mucins/.

  6. Zaha DC. Significance of immunohistochemistry in breast cancer. World J Clin Oncol. 2014;5(3):382-92. https://doi.org/10.5306/wjco.v5.i3.382

  7. The Centre for Phenogenomics. Pathology fees [Internet]. 2019 [cited 2019 Apr 20]. Available from: http://phenogenomics.ca/pathology-services.html.

  8. Department of Anatomical Pathology. Laboratory's standard operating procedure (SOP). Universitas Indonesia-Cipto Mangunkusumo Hospital. 2014.

  9. The Union for International Cancer Control. TNM classification of malignant tumours [Internet]. 2019 [cited 2019 Dec 12]. Available from: https://www.uicc.org/resources/tnm.

  10. Badowska-Kozakiewicz AM, Liszcz A, Sobol M, Patera J. Retrospectove evaluation of histopathological examination in invasive ductal breast cancer of no special type: an analysis of 691 patients. Arch Med Sci. 2017;13(6):1408-15. https://doi.org/10.5114/aoms.2015.53964

  11. Dumitru A, Procop A, Iliesiu A, Tampa M, Mitrache L, Costache A, et al. Mucinous breast cancer: a review study of 5 year experience from a hospital-based series of cases. Maedica. 2015;10(1):14-8.

  12. Ali U, Nagi AH, Naseem N, Ullah E. Mucin histochemistry in tumours of colon, ovaries and lung. J Cytol Histol. 2012;3(7):163. http://dx.doi.org/10.4172/2157-7099.1000163

  13. Fagare MO. Evaluation of mucin histo-chemical pattern in breast, colonic, ovarian and lung adenocarcinomas. Int J Life Sci Res. 2015;3(4):39-46.

  14. Cooper DJ. Mucin histochemistry of mucous carcinomas of breast and colon and non-neoplastic breast epithelium. J Clin Pathol. 1974;27(4):311-4. https://doi.org/10.1136/jcp.27.4.311

  15. Battles OE, Page DL, Johnson JE. Cytokeratins, CEA, and mucin histochemistry in the diagnosis and characterization extramammary Paget's disease. Am J Clin Pathol. 1997;108(1):6-12. https://doi.org/10.1093/ajcp/108.1.6

  16. Micke P, Botling J, Mattsson JS, Planck M, Tran L, Vidarsdottir H, et al. Mucin staining is of limited value in addition to basic immunohistochemical analyses in the diagnostics of non-small cell lung cancer. Sci Rep. 2019;9:1319. https://doi.org/10.1038/s41598-018-37722-0

  17. Jastrzebski A, Brownstein S, Jordan DR, Gilberg SM. Histochemical analysis and immunohistochemical profile of mucoepidermoid carcinoma of the conjunctiva. Saudi J Ophthalmol. 2012;26(2):205-10. https://doi.org/10.1016/j.sjopt.2012.01.004

Published
2020-03-26
How to Cite
1.
Rustamadji P, Wibowo J, Murtani B, Magdalena C. Periodic acid-Schiff and alcian blue immunohistochemistry to detect mucin in mucinous breast carcinoma. Med J Indones [Internet]. 2020Mar.26 [cited 2024Jul.3];29(1):53-7. Available from: http://mji.ui.ac.id/journal/index.php/mji/article/view/2768
Issue
Vol. 29 No. 1 (2020): March
Section
Clinical Research

Copyright (c) 2020 Primariadewi Rustamadji, Jason A. Wibowo, Belinda J. Murtani, Christy Magdalena

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with Medical Journal of Indonesia agree to the following terms:

  1. Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
  2. Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.